Related scientific articles (all)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Authors : Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA
Year : 2023
Journal : JAMA Oncol
Volume : 9
Pages : 29-39

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Authors : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L
Year : 2023
Journal : J Clin Med
Volume : 12

Liquid biopsy accelerates precision medicine.

Authors : Amato O, Aftimos P, Ignatiadis M
Year : 2023
Journal : Ann Oncol

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Authors : Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, Windhorst AD, Boellaard R, Menke-van der Houven van Oordt CW
Year : 2023
Journal : Clin Cancer Res

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.

Authors : Harding JJ, Jungels C, Machiels JP, Smith DC, Walker C, Ji T, Jiang P, Li X, Asatiani E, van Cutsem E, Abou-Alfa GK
Year : 2023
Journal : Target Oncol

Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Authors : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Year : 2023
Journal : J Natl Cancer Inst

How to deal with micronutrient product shortage - Editorial.

Authors : Joly F, Mundi M, Barazzoni R, Berger MM, Bozzetti F, Cuerda C, Jeppesen PB, Lal S, Lamprecht G, Szczepanek K, Van Gossum A, Schneider S, Shenkin A, Wanten G, Pironi L
Year : 2023
Journal : Clin Nutr
Volume : 42
Pages : 143-147

Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.

Authors : El Asmar A, Delcourt M, Kamden L, Khaled C, Bohlok A, Moreau M, Sclafani F, Donckier V, Liberale G
Year : 2023
Journal : Ann Surg Oncol
Volume : 30
Pages : 1863-1869

Linking clinical and population-based data in older patients with cancer in Belgium: Feasibility and clinical outcomes.

Authors : Depoorter V, Vanschoenbeek K, Decoster L, De Schutter H, Debruyne PR, De Groof I, Bron D, Cornélis F, Luce S, Focan C, Verschaeve V, Debugne G, Langenaeken C, Van den Bulck H, Goeminne JC, Teurfs W, Jerusalem G, Schrijvers D, Petit B, Rasschaert M, Praet JP, Vandenborre K, Milisen K, Flamaing J, Kenis C, Verdoodt F, Wildiers H
Year : 2023
Journal : J Geriatr Oncol
Pages : 101428

The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study.

Authors : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Year : 2023
Journal : Ann Surg Oncol

Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.

Authors : Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V
Year : 2023
Journal : Eur J Surg Oncol
Volume : 49
Pages : 217-224

How I treat endocrine-dependent metastatic breast cancer.

Authors : Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100882

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Authors : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Year : 2023
Journal : Eur J Cancer
Volume : 181
Pages : 92-101

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Authors : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Year : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pages : 33-41.e16

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Authors : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Year : 2023
Journal : Oncol Res Treat

Immunotherapy in breast cancer: an overview of current strategies and perspectives.

Authors : Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L
Year : 2023
Journal : NPJ Breast Cancer
Volume : 9
Pages : 7

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Authors : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Authors : Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, OShaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart-Gebhart M
Year : 2023
Journal : Eur J Cancer
Volume : 178
Pages : 23-33

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

Authors : Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A
Year : 2023
Journal : Lancet Haematol

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions.

Authors : Castelo-Branco L, Morgan G, Prelaj A, Scheffler M, Canhão H, van Meerbeeck JP, Awada A
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100764